623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II

Golseek 4 A Phase 3 randomized study of golcadomide a potential first in class oral CELMoD™ agent plus rituximab versus Investigator s choice in patients with Relapsed Refractory follicular lymphoma who have received =1 line of systemic therapy

SOUNDTRACK F1 A phase 3 randomized open label study of surovatamig AZD0486 plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma

Elevated risk of non neoplastic mortality among adolescent and young adult patients with low grade B cell lymphoma

A retrospective population based study of long term treatments and outcomes inwaldenstrom macroglobulinemia in Ontario Canada

CD20 MS4A1 mutations are strongly associated with prior chemoimmunotherapy exposure in Waldenstroem macroglobulinemia and have predicted functional consequences for the development of CD20 directed cellular therapies

Increasing incidences in primary lung marginal zone lymphoma A SEER database analysis

Phase 2 trial of cladribine plus immediate rituximab for 1st line treatment of hairy cell leukemia – long term follow up of original and additional patient cohorts

Quantitative 18F FDG PET CT analysis of splenic suvmax enhances diagnostic accuracy in primary splenic non Hodgkin lymphoma

Real world effectiveness and safety outcomes by age comorbidities and frailty among relapsed or refractory R R Mantle Cell Lymphoma MCL patients treated with brexucabtagene autoleucel brexu cel

Impact of baseline suvmax in untreated high tumor burden follicular lymphoma

Glofitamab and obinutuzumab GLOBIN as first line therapy for patients with high tumor burden follicular lymphoma First results of a multicenter phase II trial

Prognostic impact of diagnosis to treatment interval in follicular lymphoma patients treated with immunochemotherapy Evidence from an international cohort with independent validation

Odronextamab plus chemotherapy in patients with previously untreated follicular lymphoma First results from part 1 of the Phase 3 Olympia 2 study

Efficacy and safety of first line orelabrutinib combined with obinutuzumab With or Without Bendamustine in high risk marginal zone lymphoma Results from the orchid study

EO2463 EO peptide immunotherapy combined with rituximab R for first line treatment of low tumor burden follicular lymphoma FL A feasibility evaluation in Study EONHL1 20 sidney NCT04669171

Prognostic significance of clinical risk models and genomic alterations in Waldenstroem macroglobulinemia before or after BTK inhibitor era

Characterization and outcomes of patients with indolent Mantle Cell Lymphoma iMCL in Spain the GELTAMO MCL 2022 Study

Genomic characterization uncovers molecular subtypes in Mantle Cell Lymphoma

Heterogeneous TP53 mutation subtypes define prognostic classification in Mantle Cell Lymphoma

Efficacy and safety of long term odronextamab treatment in patients with relapsed refractory follicular lymphoma 3 year follow up from the Phase 2 ELM 2 study

Real world treatment and outcomes of Mantle Cell Lymphoma in Latin America A multinational cohort analysis

Central nervous system involvement in Mantle Cell Lymphoma A retrospective multicenter cohort study from the spanish geltamo group

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB 16673 in patients with relapsed refractory indolent non Hodgkin lymphoma from the ongoing phase 1 CaDAnCe 101 study

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB 16673 in patients with relapsed refractory Waldenstroem macroglobulinemia from the ongoing phase 1 CaDAnCe 101 study

Phase 3 study inMIND of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma Clinical characteristics and outcomes by age

Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG ACRIN E1411 study of bendamustine rituximab bortezomib and maintenance with rituximab lenalidomide

Preliminary study results of orelabrutinib in combination with rituximab for treatment Naïve marginal zone lymphoma A prospective single arm clinical trial

Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine rituximab with or without acalabrutinib in the phase 3 ECHO trial

Venetoclax or pirtobrutinib in relapsed refractory Waldenstroem macroglobulinemia Clinical and molecular predictors and sequencing implications

Plasma protein ADAMTS8 as a minimally invasive favorable prognostic biomarker in mantle cell lymphoma

Outcomes from the Multicenter ACCRU LY 1804 CARiBOU Cytarabine Acalabrutinib and Rituximab integrated with Bortezomib based Outpatient therapy Trial in 1st line Mantle Cell Lymphoma

Phase II study of bendamustine rituximab and venetoclax BR VEN for the front line treatment of Mantle Cell Lymphoma MCL in patients =60 years old Updated survival and minimal residual disease MRD analysis of precog PrE0405

Impact of treatment facility type on survival outcomes in mantle cell lymphoma A 20 year NCDB analysis

Nemtabrutinib in participants with relapsed or refractory follicular lymphoma Updated efficacy and safety from cohort g of the phase 2 bellwave 003 study